Palisade Bio Financials - Benzinga

Palisade Bio Inc

PALINASDAQ

Trade with Public

Trade with Public

$2.02

-0.025-1.22%

Last update: Sep 10, 2:11 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Palisade Bio Financials

Palisade Bio (PALI) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000K

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 91.38 percent increase over losses of $(0.58) per share from the same period last year. The

Benzinga Newsdesk

PRO
Palisade Bio Q1 EPS $(0.05) Misses $(0.04) Estimate

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 89.36 percent increase over losses of $(0.47) per share from the

Benzinga Newsdesk

Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December

Avi Kapoor

PRO
Palisade Bio Q3 EPS $(0.38) Misses $(0.27) Estimate

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.27) by 39.19 percent. This is a 83.62 percent increase over losses of $(2.32) per share from

Benzinga Newsdesk

PRO
Palisade Bio Q1 EPS $(0.47) Beats $(0.70) Estimate

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.70) by 32.86 percent. This is a 89.76 percent increase over losses of $(4.59) per share from the

Benzinga Newsdesk

Nasdaq Down 50 Points; US Initial Jobless Claims Rise

Avi Kapoor